Mark Knapp

3.5k citations

24 papers · 1.2k indexed · h-index 17

Genetics top 10%
- Chronic Lymphocytic Leukemia Research 2
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer 7
- Biochemical and Molecular Research 4
- DNA Repair Mechanisms 2
Organic Chemistry top 10%
- Quinazolinone synthesis and applications 4
- Synthesis and biological activity 2
Neurology top 10%
- Botulinum Toxin and Related Neurological Disorders 3
Pharmaceutical Science top 10%
Infectious Diseases
- SARS-CoV-2 and COVID-19 Research 2

Co-authors: Bernhard Rupp Julie Morrow Michael C. Phillips Mark L. Segall Sissel Lund‐Katz Karl H. Weisgraber Pascal Furet Joachim Blanz
Cited by: Genetics Molecular Biology Organic Chemistry
Journals: Bioorganic & Medicinal Chemistry Letters (5 papers)ACS Medicinal Chemistry Letters (4 papers)Protein Expression and Purification (2 papers)
Partner nations: United States Switzerland China

In The Last Decade

Mark Knapp

24 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark Knapp

Since Specialization

Citations

This map shows the geographic impact of Mark Knapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Knapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Knapp more than expected).

Fields of papers citing papers by Mark Knapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Knapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Knapp. The network helps show where Mark Knapp may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark Knapp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Knapp Line = papers co-authored together Mark Knapp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses Viruses ·Sarah N. Zvornicanin,Ala M. Shaqra,Qiu Yu J. Huang,Elizabeth Ornelas,Emily Ann Shick,Mark Knapp,Stephanie Moquin,Dustin Dovala,Celia A. Schiffer,Neşe Kurt Yılmaz	2023	5
2	Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance Nature Communications ·Ala M. Shaqra,Sarah N. Zvornicanin,Qiu Yu J. Huang,G.J. Lockbaum,Mark Knapp,Laura Tandeske,Kerry Cleary,Julia M. Flynn,Daniel N. Bolon,Stephanie Moquin,Dustin Dovala,Neşe Kurt Yılmaz,Celia A. Schiffer	2022	73
3	A polyomavirus peptide binds to the capsid VP1 pore and has potent antiviral activity against BK and JC polyomaviruses eLife ·L. H. Miller,Susan Fong,Alfredo Castillo-Cira,Alexandra Frommlet,Andreas O. Frank,Mark Knapp,Dirksen E. Bussiere,Peter Kim,Elizabeth Ornelas,Haitao Wang,Graciela Teruel-Belismelis,Johanna R. Abend,Charles Wartchow	2020	7
4	Preclinical Characterization of MAU868, a Novel Neutralizing Antibody Targeting BK Virus Journal of the American Society of Nephrology ·Qi Shao,Mark Knapp,Inhag Park Park,Peter Kim,Andreas Hein,Meike Scharenberg,Alfredo Castillo-Cira,Kelly A. Wong,Steven J. Kovacs,Elisabetta Traggiai,Amy K. Patick,Johanna R. Abend	2020	1
5	Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors Journal of Molecular Biology ·Yipin Lu,Mark Knapp,Kenneth Crawford,Robert Warne,R.A. Elling,Kelly Yan,Michael Doyle,Gwynn Pardee,Li Zhang,Sylvia Ma,Mulugeta Mamo,Elizabeth Ornelas,Yue Pan,Dirksen E. Bussiere,Johanna M. Jansen,Isabel Zaror,Albert Lai,Paul A. Barsanti,Janet Sim	2017	28
6	Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model Bioorganic & Medicinal Chemistry Letters ·Wooseok Han,Daniel L. Menezes,Yongjin Xu,Mark Knapp,R.A. Elling,Matthew T. Burger,Zhi‐Jie Ni,Aaron Smith,Jiong Lan,美知子灰田,Joelle Verhagen,Kay Huh,Hanne Merritt,John S.D. Chan,Susan Kaufman,Charles F. Voliva,Sabina Pecchi	2016	20
7	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors ACS Medicinal Chemistry Letters ·Klemens Hoegenauer,Nicolas Soldermann,Frédéric Stauffer,Pascal Furet,A J Cooper,Alexander B. Smith,Long Jiangtao,Gregory J. Hollingworth,Ian Lewis,Sascha Gutmann,Gabriele Rummel,Mark Knapp,Romain M. Wolf,Joachim Blanz,Roland Feifel,Christoph Burkhart,Frédéric J. Zécri	2016	49
8	Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors Bioorganic & Medicinal Chemistry Letters ·Robin A. Fairhurst,Marc Gerspacher,Patricia Imbach‐Weese,Robert Mah,Giorgio Caravatti,Pascal Furet,Christine Fritsch,Christian Schnell,Joachim Blanz,Francesca Blasco,Sandrine Desrayaud,Daniel Guthy,Mark Knapp,จุฑาทิพย์ นามวงษ์,منى محمد سعید خمیس عرفه,丰晓流,藤井泉	2015	15
9	Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo ACS Medicinal Chemistry Letters ·Ayako Honda,Edmund Harrington,Iván Cornella‐Taracido,Pascal Furet,Mark Knapp,Meir Glick,Ellen Triantafellow,William E. Dowdle,Jurgen North,Wieslawa Maniara,Christine Moore,Peter M. Finan,Lawrence G. Hamann,Brant Firestone,Leon O. Murphy,Erin P. Keaney	2015	40
10	Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K Bioorganic & Medicinal Chemistry Letters ·Sabina Pecchi,Zhi‐Jie Ni,Wooseok Han,Aaron Smith,Jiong Lan,Matthew T. Burger,Hanne Merritt,Marion Wiesmann,John S.D. Chan,Susan Kaufman,Mark Knapp,L. Bailoni,Kay Huh,Charles F. Voliva	2013	6
11	Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation Bioorganic & Medicinal Chemistry Letters ·Pascal Furet,Vito Guagnano,Robin A. Fairhurst,Patricia Imbach‐Weese,Ian C. Bruce,Mark Knapp,Christine Fritsch,Francesca Blasco,Joachim Blanz,Reiner Aichholz,Jacques Hamon,Doriano Fabbro,Giorgio Caravatti	2013	350
12	Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Sabina Pecchi,Paul A. Renhowe,Clarke Taylor,Susan Kaufman,Hanne Merritt,Marion Wiesmann,Kevin Shoemaker,Mark Knapp,Elizabeth Ornelas,Thomas F. Hendrickson,Wendy J. Fantl,Charles F. Voliva	2010	24
13	Targeting Cancer: The Challenges and Successes of Structure-Based Drug Design Against the Human Purinome Current Topics in Medicinal Chemistry ·Mark Knapp,Cornelia Bellamacina,Jeremy Murray,Dirksen E. Bussiere	2006	13
14	Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity Proceedings of the National Academy of Sciences ·Brent W. Segelke,Mark Knapp,Saloumeh Kadkhodayan,Rod Balhorn,Bernhard Rupp	2004	77
15	Do Enzymes Change the Nature of Transition States? Mapping the Transition State for General Acid−Base Catalysis of a Serine Protease Biochemistry ·R. Bott,Gina Chan,A. Manzueta,Grant Ganshaw,Constance Y. Hsia,Mark Knapp,Christopher J L Murray	2003	16
16	Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC‐IIα Protein Science ·Heike I. Krupka,Brent W. Segelke,Robert G. Ulrich,Krzysztof Mrozowski,Mark Knapp,Bernhard Rupp	2002	7
17	Identification of Novel Small Molecule Ligands That Bind to Tetanus Toxin Chemical Research in Toxicology ·Felice C. Lightstone,Aileen Burford Mason,Anup K. Singh,M.C. Piqueras,Randy M. Whittal,Mark Knapp,Rod Balhorn,Diana C. Roe	2000	25
18	Cloning, Expression, and One-Step Purification of the Minimal Essential Domain of the Light Chain of Botulinum Neurotoxin Type A Protein Expression and Purification ·Saloumeh Kadkhodayan,Mark Knapp,James J. Schmidt,Mônica da Silva Buono,Bernhard Rupp,Rod Balhorn	2000	23
19	Differences in Stability among the Human Apolipoprotein E Isoforms Determined by the Amino-Terminal Domain Biochemistry ·Julie Morrow,Mark L. Segall,Sissel Lund‐Katz,Michael C. Phillips,Mark Knapp,Bernhard Rupp,Karl H. Weisgraber	2000	274
20	Carboxyl-Terminal Domain of Human Apolipoprotein E: Expression, Purification, and Crystallization Protein Expression and Purification ·Michael Forstner,Clare Peters‐Libeu,Adolfo Esquivel Villarreal,Yvonne M. Newhouse,Mark Knapp,Bernhard Rupp,Karl H. Weisgraber	1999	25

About Mark Knapp

Mark Knapp is a scholar working on Molecular Biology, Physiology and Neurology, having authored 24 papers that have together received 1.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), Biochemical and Molecular Research (4 papers), Quinazolinone synthesis and applications (4 papers), Botulinum Toxin and Related Neurological Disorders (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Synthesis and biological activity (2 papers), DNA Repair Mechanisms (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Genetics (127 citations), Molecular Biology (769 citations) and Organic Chemistry (219 citations). Mark Knapp has collaborated with scholars based in United States, Switzerland and China. Frequent co-authors include Bernhard Rupp, Julie Morrow, Michael C. Phillips, Mark L. Segall, Sissel Lund‐Katz, Karl H. Weisgraber, Pascal Furet, Joachim Blanz, Christine Fritsch and Giorgio Caravatti. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, ACS Medicinal Chemistry Letters, Protein Expression and Purification, Proceedings of the National Academy of Sciences and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact